The internalization of <i>Helicobacter pylori</i> plays a role in the failure of <i>H. pylori</i> eradication

Wang, Youhua; Lv, Zhifa; Zhong, Yao; Li, Dongsheng; Chen, Shuping; Xie, Yong

doi:10.1111/hel.12324

Cited by 31 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such a process might be a strategy for H. pylori to escape immune surveillance and remain alive in vivo (Amieva et al, 2002; Dubois and Borén, 2007), and it contributes to the complication of eradication. To determine whether H. pylori internalization plays a role in treatment failure, one study (Wang et al, 2016) carried out in our laboratory applied an invasion assay to evaluate the levels of H. pylori invasion of GES-1 cells. The results showed that the internalization levels of the failing strains were higher than those of the successful strains.…”

Section: Cellular Invasion Of H Pylorimentioning

confidence: 99%

“…The results showed that the internalization levels of the failing strains were higher than those of the successful strains. However, there is no consensus regarding whether the level of internalization is related to antibiotic resistance, with some studies considering that resistant strains are associated with significantly higher internalization activity than susceptible strains (Lai et al, 2006) but Wang et al (2016) reporting no evidence of this. Regardless of the correlation, once therapy fails, more consideration should be given to H. pylo ri internalization activity.…”

Section: Cellular Invasion Of H Pylorimentioning

confidence: 99%

See 1 more Smart Citation

Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori

Huang

Wang

Cheng

et al. 2016

Front. Cell. Infect. Microbiol.

103

View full text Add to dashboard Cite

Helicobacter pylori is the main pathogenic bacterium involved in chronic gastritis and peptic ulcer and a class 1 carcinogen in gastric cancer. Current research focuses on the pathogenicity of H. pylori and the mechanism by which it colonizes the gastric mucosa. An increasing number of in vivo and in vitro studies demonstrate that H. pylori can invade and proliferate in epithelial cells, suggesting that this process might play an important role in disease induction, immune escape and chronic infection. Therefore, to explore the process and mechanism of adhesion and invasion of gastric mucosa epithelial cells by H. pylori is particularly important. This review examines the relevant studies and describes evidence regarding the adhesion to and invasion of gastric mucosa epithelial cells by H. pylori.

show abstract

Section: Cellular Invasion Of H Pylorimentioning

confidence: 99%

Section: Cellular Invasion Of H Pylorimentioning

confidence: 99%

Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori

Huang

Wang

Cheng

et al. 2016

Front. Cell. Infect. Microbiol.

103

View full text Add to dashboard Cite

show abstract

“…They consist of a PPI plus three antimicrobials: metronidazole, tetracycline, and bismuth in the first therapy and metronidazole, amoxicillin, and clarithromycin in the second one [14,15]. These last regimens seem the most effective ones to overcome antibiotic resistance, the main proposed reason of treatment failure together with low patient compliance to therapy, high gastric bacterial load, cytochrome P450 polymorphism (CYP2C19), and high gastric acidity [16]. Antibiotic resistance to Hp has been suggested to arise from point mutations, drug inactivation, the activation of drug efflux pumps, altered membrane permeability, biofilm formation or the presence of bacterial dormant forms [17].…”

Section: Introductionmentioning

confidence: 99%

Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens

Salillas

Sancho

2020

IJMS

View full text Add to dashboard Cite

Flavodoxins are small soluble electron transfer proteins widely present in bacteria and absent in vertebrates. Flavodoxins participate in different metabolic pathways and, in some bacteria, they have been shown to be essential proteins representing promising therapeutic targets to fight bacterial infections. Using purified flavodoxin and chemical libraries, leads can be identified that block flavodoxin function and act as bactericidal molecules, as it has been demonstrated for Helicobacter pylori (Hp), the most prevalent human gastric pathogen. Increasing antimicrobial resistance by this bacterium has led current therapies to lose effectiveness, so alternative treatments are urgently required. Here, we summarize, with a focus on flavodoxin, opportunities for pharmacological intervention offered by the potential protein targets described for this bacterium and provide information on other gastrointestinal pathogens and also on bacteria from the gut microbiota that contain flavodoxin. The process of discovery and development of novel antimicrobials specific for Hp flavodoxin that is being carried out in our group is explained, as it can be extrapolated to the discovery of inhibitors specific for other gastric pathogens. The high specificity for Hp of the antimicrobials developed may be of help to reduce damage to the gut microbiota and to slow down the development of resistant Hp mutants.

show abstract

“…Currently, this regimen is unacceptable as a first-line therapy for H. pylori (Graham and Fischbach, 2010). Several factors are involved in failed H. pylori eradication, including improper regimens, poor patient compliance, massive gastric bacterial loads, internalizing bacteria, high gastric acidity, gene polymorphisms (IL-1B and CYP2C19), antimicrobial washout and dilution, biofilm formation, and most importantly, resistance to antibiotics (Graham and Dore, 2016; Malfertheiner et al, 2016; Wang et al, 2017). During recent decades, the rate of antibiotic resistance (particularly to clarithromycin) has rapidly increased in most countries around the world (Thung et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Zhu

Lü

2017

Front. Cell. Infect. Microbiol.

130

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. Helicobacter pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth-containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility-based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

show abstract

The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication

Abstract: The results showed that H. pylori invasion of the gastric epithelia might play a role in eradication failure.

Cited by 31 publications

References 36 publications

Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori

Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori

Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Contact Info

Product

Resources

About